

Short Communication

ras Mutations are Uncommon in Nasopharyngeal Carcinoma

W.C.W. Yung, J.S.T. Sham, D.T.K. Choy and M.H. Ng

NASOPHARYNGEAL CARCINOMA (NPC) is one of the most common cancers in Southern China. The *ras* gene was detected in these tumours by a previous transfection study [1]. However, there has been no report of direct examination of the status of the *ras* genes in these tumours.

In this study, we examined 18 NPC tumours for mutations of *Ha-ras*, *Ki-ras* and *N-ras* at codons 12, 13 and 61, which are the mutational hotspots of this gene family, using allele-specific oligonucleotide hybridisation as described by Verlaan de-Vries *et al.* [2]. The tumour samples included three xenografts (666, 1915, 2117) which were WHO III (undifferentiated), three WHO II (poorly differentiated) and 12 WHO III biopsies. Four of the WHO III biopsies were obtained from secondary tumours located at the regional lymph nodes and the others were primary tumours. Four control cell lines: HT1080, HL60, SW480 and MOLT4, were used as positive controls for hybridisation, as described by Verlaan de-Vries *et al.* [2].

DNA was extracted from the tumours as described in [3]. The primers and oligonucleotide probes for PCR were the same as those used by Verlaan de-Vries *et al.* [2]. The PCR cycles used were: 94°C, 30 s; 55°C, 1 min and 72°C, 1 min (for *Ha-ras* and *Ki-ras*), while the annealing temperature for *N-ras* was 49°C. Thirty cycles were performed, followed by an extension at 72°C for 7 min, using TC-1 tempcycler (Perkin-Elmer). The PCR products were run on a 2–2.5% TBE gel and Southern-blotted. Hybridisation was performed according to the procedures in [2].

Under the hybridisation conditions used, only PCR products from cell lines carrying *ras* mutations exclusively hybridised with probes which were specific for the corresponding mutant alleles. PCR products from the tumour samples studied hybridised only with wild-type probes while the water blank control consistently showed no hybridisation. An example of the results, in this case *N-ras*, is shown in Fig. 1.




Fig. 1. Analysis of *N-ras* codon 61 mutations. Hybridisation using wild-type oligoprobes identified PCR products (103 base pairs) of all NPC samples. Lane 0 is the DNA blank control (a). Hybridisation with mutant probe pools N61P1 (b) and N61P2 (c) encompass all possible mutations in the first and second base positions of codon 61, respectively. Only the positive cell lines, HT1080 (b) and HL60 (c) gave positive signals.

The patterns of hybridisation were confirmed by reproducing the experiments at least twice.

None of the NPC specimens examined in this study contained *ras* mutations at the hotspots. However, the possibility that novel mutations occur in other locations of the *ras* genes cannot be excluded, even though these are rarely found in natural tumours. Recently, the *ras* products have been found to be overexpressed in NPC [4], suggesting the possible involvement of *ras* proteins in the pathogenesis of NPC. It seems possible that some epigenetic events may occur that lead to upregulation of the proteins. The *ras* proteins have been shown to be transforming when overexpressed, even though the proteins are wild type [5].

Alternatively, *ras* activation may be replaced by other events that produce similar effects. It has been shown that nearly all NPCs harbour deletions on chromosome 3p, near the *raf-1* locus [6]. Since this gene encodes a serine/threonine kinase that interacts directly with the *ras* products, aberration of this gene may substitute *ras* mutations. In addition, a human herpes virus, EBV, is regularly associated with NPC. One EBV transforming protein, LMP-1, shares homology to the rhodopsin family [7]. This family comprises receptors coupled with G proteins. Since the *ras* proteins are members of the G protein family, expression of LMP-1 may obviate the need for *ras* mutations in those tumours that express this protein.

Correspondence to W.C.W. Yung at the Department of Zoology, Chong Yuet Ming Physics Building, The University of Hong Kong, Hong Kong.

W.C.W. Yung and M.H. Ng are at the Department of Microbiology, The University of Hong Kong; J.S.T. Sham is at the Department of Radiation Oncology, The University of Hong Kong, Hong Kong; and D.T.K. Choy is at the Department of Radiotherapy and Oncology, Queen Mary Hospital, Town/City, Country.
Received 21 Feb. 1995; provisionally accepted 18 April 1995; revised manuscript received 17 July 1995.

In conclusion, activating *ras* mutations at codons 12, 13 and 61 are relatively uncommon in NPCs. However, in view of the reported overexpression of *ras* products in NPCs [5], the involvement of the *ras* genes in NPC cannot be entirely excluded. Alternatively, other events that mimic the effects of *ras* mutation may occur in NPCs. The exact nature of such events warrants further investigation.

1. Hu LF, Li XL, Jiang JQ, *et al.* Transforming activity of human nasopharyngeal carcinoma DNA. *J Cell Physiol (Supp)* 1986, **4**, 21–26.
2. Verlaan-de Vries M, Bogaard ME, Elst H van den, Boom JH van, Eb AJ van der, Bos JL. A dot-blot screening procedure for mutated *ras* oncogenes using synthetic oligodeoxynucleotides. *Gene* 1986, **50**, 313–320.
3. Ausubel FM, Brent R, Kingston RE, *et al.* *Current Protocols in Molecular Biology*. New York, John Wiley, 1987.
4. Porter MJ, Field JK, Leung SF, *et al.* The detection of the *c-myc* and *ras* oncogenes in nasopharyngeal carcinoma by immunohistochemistry. *Acta Otolaryngol (Stockh)* 1994, **114**, 105–109.
5. Chang EH, Furth ME, Scolnick EM, Lowry DR. Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. *Nature* 1982, **297**, 479–483.
6. Huang DP, Lo KW, Choi PHK, *et al.* Loss of heterozygosity on the short arm of chromosome 3 in nasopharyngeal carcinoma. *Cancer Genet Cytogenet* 1991, **54**, 91–99.
7. Fennewald S, Santen V van, Kieff E. Nucleotide sequence of an mRNA transcribed in latent growth transforming virus infection indicates that it may encode a membrane protein. *J Virol* 1984, **51**, 411–419.

Acknowledgement—This work was carried out by W.C.W. Yung in partial fulfillment of the degree of Master of Philosophy at the University of Hong Kong.